title: Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1.
abstract: The recent report that clopidogrel efficacy may be more dependent on paraoxonase-1 (PON1) than on cytochrome P450 2C19 (CYP2C19) activity raises questions about the roles of these and other enzymes in clopidogrel activation. To provide insight into the emerging PON1 versus CYP2C19 debate, this commentary summarizes the clinical evidence on the pharmacokinetic determinants of clopidogrel efficacy. We then review the in vitro studies investigating the enzymes involved in clopidogrel activation, and comment on their strengths and limitations. There is agreement amongst in vitro studies regarding the involvement of CYP1A2 and CYP2B6 in the metabolism of clopidogrel to 2-oxo-clopidogrel. However, the evidence for other CYP enzymes in the first activation step (e.g. CYP2C19 and CYP3A4) is inconsistent and dependent on the in vitro test system and laboratory. All major drug metabolizing CYP enzymes are capable of converting 2-oxo-clopidogrel to sulfenic acid intermediates that subsequently form the active thiol metabolite. However, the extent of CYP involvement in this second step has been challenged, and new evidence suggests that CYP-independent hydrolytic cleavage of the thioester bond may be more important than oxidative metabolism.
authors.affiliation: Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Sturt Road, Bedford Park, Adelaide, SA 5042, Australia.
authors.forename: Thomas M
authors.initials: TM
authors.lastname: Polasek
authors.affiliation: Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, Australia.
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Doogue
authors.affiliation: Department of Clinical Pharmacology, Flinders University and Flinders Medical Centre, Adelaide, Australia.
authors.forename: John O
authors.initials: JO
authors.lastname: Miners
keywords: antiplatelet; clopidogrel; cytochrome P4502C19; metabolic activation; paraoxonase-1; pharmacogenomics
references.citation: Chem Res Toxicol. 2009 Feb;22(2):369-73
references.pmid: 19170597
references.citation: Br J Clin Pharmacol. 2007 Oct;64(4):450-7
references.pmid: 17517049
references.citation: J Am Coll Cardiol. 2011 Mar 15;57(11):1251-63
references.pmid: 21392639
references.citation: Nat Med. 2011 Jan;17(1):110-6
references.pmid: 21170047
references.citation: Xenobiotica. 2009 Nov;39(11):836-43
references.pmid: 19845434
references.citation: Biochem Pharmacol. 1992 Aug 4;44(3):527-32
references.pmid: 1510701
references.citation: JAMA. 2010 Oct 27;304(16):1821-30
references.pmid: 20978260
references.citation: Circulation. 2010 Aug 3;122(5):537-57
references.pmid: 20585015
references.citation: Drug Metab Dispos. 2002 Nov;30(11):1288-95
references.pmid: 12386137
references.citation: Circulation. 2003 Jan 7;107(1):32-7
references.pmid: 12515739
references.citation: JAMA. 2009 Aug 26;302(8):849-57
references.pmid: 19706858
references.citation: J Pharmacol Exp Ther. 2006 Dec;319(3):1467-76
references.pmid: 16943252
references.citation: Drug Metab Dispos. 2003 Jan;31(1):53-9
references.pmid: 12485953
references.citation: AAPS J. 2008;10(1):200-7
references.pmid: 18446520
references.citation: Toxicol In Vitro. 2011 Jun;25(4):905-13
references.pmid: 21382471
references.citation: Nat Med. 2011 Jan;17(1):40-1
references.pmid: 21217678
references.citation: Circulation. 2010 Feb 2;121(4):512-8
references.pmid: 20083681
references.citation: Xenobiotica. 1994 Dec;24(12):1151-75
references.pmid: 7771104
references.citation: Thromb Haemost. 1994 Aug;72(2):313-7
references.pmid: 7831671
references.citation: Clin Pharmacol Ther. 2011 Mar;89(3):464-7
references.pmid: 21270786
references.citation: Drug Metab Dispos. 2010 Jan;38(1):92-9
references.pmid: 19812348
references.citation: Eur Heart J. 2011 Jul;32(13):1605-13
references.pmid: 21527445
references.citation: J Pharmacol Exp Ther. 1993 Jan;264(1):89-94
references.pmid: 8423554
references.citation: Arch Biochem Biophys. 1993 Oct;306(1):240-5
references.pmid: 8215410
references.citation: Drug Metab Dispos. 2009 Nov;37(11):2145-52
references.pmid: 19704027
references.citation: Thromb Haemost. 2000 Nov;84(5):891-6
references.pmid: 11127873
references.citation: Thromb Haemost. 2010 Apr;103(4):841-8
references.pmid: 20135063
references.citation: Clin Exp Pharmacol Physiol. 2002 Nov;29(11):1040-4
references.pmid: 12366399